Gilead Sciences GILD
SEC filings (XBRL) · quarterly · fiscal year ends December 31
Pick a second metric to compare.
Source: SEC EDGAR 10-Q/10-K XBRL, CIK 882095; every value is traced to its filing on EDGAR. Retrieved Oct 11, 2026. Quarters labelled by fiscal quarter with the calendar period end. Q4 = annual minus Q1–Q3; cash-flow quarters derived from year-to-date figures.
Last 84 quarters
| Q3 2024Sep 30, 2024 | Q4 2024Dec 31, 2024 | Q1 2025Mar 31, 2025 | Q2 2025Jun 30, 2025 | Q3 2025Sep 30, 2025 | Q4 2025Dec 31, 2025 | Q1 2026Mar 31, 2026 | Q2 2026Jun 30, 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.5B | $7.6B | $6.7B | $7.1B | $7.8B | $7.9B | $7.0B | $7.8B |
| Operating income | $0.9B | $2.5B | $2.2B | $2.5B | $3.3B | $2.0B | $2.6B | −$10.4B |
| Net income | $1.3B | $1.8B | $1.3B | $2.0B | $3.1B | $2.2B | $2.0B | −$10.5B |
| Capital spending | $0.1B | $0.1B | $0.1B | $0.1B | $0.1B | $0.2B | $0.1B | $0.1B |
| Operating cash flow | $4.3B | $3.0B | $1.8B | $0.8B | $4.1B | $3.3B | $2.5B | $3.6B |
| Free cash flow | $4.2B | $2.8B | $1.7B | $0.7B | $4.0B | $3.1B | $2.4B | $3.4B |
| Capex / operating cash flow | 3.3% | 4.9% | 5.9% | 12.9% | 3.6% | 6.2% | 4.6% | 3.9% |
| Shares outstanding | 1.246B | 1.245B | 1.244B | 1.241B | 1.241B | 1.241B | 1.242B | 1.240B |
| Share count change, y/y | +0.0% | −0.0% | −0.2% | −0.3% | −0.4% | −0.3% | −0.2% | −0.1% |
| Diluted shares (weighted avg.) | 1.254B | — No figure for Q4 2024: fiscal Q4: the 10-K presents no 3-month weighted average; never derived | 1.259B | 1.255B | 1.254B | — No figure for Q4 2025: fiscal Q4: the 10-K presents no 3-month weighted average; never derived | 1.254B | 1.243B |
— Diluted shares (weighted avg.): No figure for Q4 2024: fiscal Q4: the 10-K presents no 3-month weighted average; never derived
— Diluted shares (weighted avg.): No figure for Q4 2025: fiscal Q4: the 10-K presents no 3-month weighted average; never derived
Diluted shares (weighted avg.): fiscal Q4 is blank because the 10-K gives 12-month figures only.
XBRL tags used
| Revenue | Revenues | Mar 2017 to Dec 2017 |
|---|---|---|
RevenueFromContractWithCustomerExcludingAssessedTax | Mar 2018 to Jun 2026 | |
| Operating income | OperatingIncomeLoss | Mar 2017 to Jun 2026 |
| Net income | NetIncomeLoss | Mar 2017 to Jun 2026 |
| Capital spending | PaymentsToAcquirePropertyPlantAndEquipment | Mar 2017 to Jun 2026 |
| Operating cash flow | NetCashProvidedByUsedInOperatingActivities | Mar 2017 to Jun 2026 |
| Free cash flow | ocf - capex: NetCashProvidedByUsedInOperatingActivities, PaymentsToAcquirePropertyPlantAndEquipment | Mar 2017 to Jun 2026 |
| Capex / operating cash flow | capex / ocf * 100: PaymentsToAcquirePropertyPlantAndEquipment, NetCashProvidedByUsedInOperatingActivities | Mar 2017 to Jun 2026 |
| Shares outstanding | dei:EntityCommonStockSharesOutstanding | Mar 2017 to Jun 2026 |
| Diluted shares (weighted avg.) | WeightedAverageNumberOfDilutedSharesOutstanding | Mar 2017 to Jun 2026 |
Where a company changed tags, each quarter uses the tag it was reported under; the newest tag is primary.